. Author manuscript; available in PMC: 2020 Oct 1.

Published in final edited form as: CNS Drugs. 2019 Oct;33(10):1001–1030. doi: 10.1007/s40263-019-00664-w

Table 4.

Effects of monoacylglycerol lipase inhibitors on drug-taking and drug-seeking behavior in experimental animals

Drug and dosage	Species	Results	References
JZL184
IP 16 mg/kg	Mouse	↓ Withdrawal symptoms from Δ⁹-THC	[218]
IP 40 mg/kg	Mouse	↓ Somatic signs of morphine withdrawal	[180]
IP 16 mg/kg	Mouse	↓ Methamphetamine-induced DA neurotoxicity	[215]
IP 4, 40 mg/kg	Mouse	↓ Brain-stimulation reward	[75]
IP 4–40 mg/kg	Mouse	↓ Nicotine withdrawal symptoms	[219]
IP 4, 40 mg/kg	Mouse	No effect on naloxone-precipitated CPA	[220]
IP 4, 40 mg/kg	Mouse	↓ Somatic signs of morphine withdrawal	[220]
IP 8, 16 mg/kg	Mouse	No effect on food taking	[13]
		No effect on nicotine taking
		No effect on PR responding for nicotine
		↑ Cue-induced reinstatement of nicotine seeking
IP 2–18 mg/kg	Mouse	↑ PR responding for alcohol	[226]
SA-57
IP 1–13 mg/kg	Mouse	↓ Somatic signs of morphine withdrawal	[220]
IP 1–13 mg/kg	Mouse	No effect on naloxone-induced CPA	[220]
IP 3–18 mg/kg	Mouse	↓ Brain-stimulation reward	[75]
IP 1–13 mg/kg	Mouse	↓ Heroin self-administration	[221]
		↓ PR responding for heroin
		↓ Cue-induced reinstatement of heroin seeking

CPA conditioned place aversion, DA dopamine, IP intraperitoneally, PR progressive-ratio, Δ⁹-THC Δ⁹-tetrahydrocannabinol, ↓ and ↑ represent decrease and increase, respectively